Emergent BioSolutions Inc. (EBS), a public health company, on Monday announced that the Board has authorized the repurchase of up to $50 million of stock on or before March 27, 2026.
As of December 31, 2024, the company had around 54.3 million outstanding common shares.
In the pre-market trading, Emergent is 3.65% higher at $4.83 on the Nasdaq.
For comments and feedback: editorial@rttnews.com